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List of Abbreviations 
6-O-CAPRO-β-CD amphiphilic CD derivative modified on the primary face with 6C 
aliphatic esters 
ABC   ATPase binding cassettes transporters 
BCS   Biopharmaceutical Classification System 
CD   cyclodextrin 
CDs   cyclodextrins 
α-CD   α-cyclodextrin 
β-CD   β-cyclodextrin 
β-CDC6 amphiphilic β-cyclodextrin modified on the secondary face with 
6C aliphatic esters, 
γ-CD   γ-cyclodextrin 
CYP450  cytochrome P450 
DMβCD  dimethyl-β-cyclodextrin 
E2   17-β-estradiol 
EXE   exemestane 
HPβCD  hydroxypropyl-β-cyclodextrin 
HPγCD  hydroxypropyl-γ-cyclodextrin 
iv   intravenous 
MβCD   randomly methylated-β-cyclodextrin 
PCL   poly(ε-caprolactone) 
PLA   poly(lactic acid)  
PLGA   poly(lactic-co-glycolic acid) 
Pgp   P-glycoprotein 
SBEβCD  sulfobuthylether- β-cyclodextrin 
TMβCD  trimethyl-β-cyclodextrin 
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Abstract 
The oral route is preferred by patients for drug administration due to its 
convenience resulting in improved compliance. Unfortunately, for a number of 
drugs (i.e. anticancer drugs), this route of administration remains a challenge. Oral 
chemotherapy may be an attractive option and especially appropriate for chronic 
treatment of cancer. However, this route of administration is particularly 
complicated for the administration of anticancer drugs ascribed to the Class IV of 
the Biopharmaceutical Classification System. This group of compounds is 
characterised by a low aqueous solubility and low intestinal permeability. This 
review focuses on the use of cyclodextrins alone or in combination with 
bioadhesive nanoparticles for oral delivery of drugs. The state-of-the-art technology 
and challenges in this area is also discussed. 
 
 
Keywords and Defined Keyterms 
 
1. Nanoparticles: vehicles of submicronic size for drug delivery purposes   
2. Cyclodextrins: solubilising excipients with certain ability to disturb p-
glycoprotein and cytochrome P450 activities characterised by a unique shape of a 
truncated cone. 
3. Oral: one of the most accepted routes of drug administration by patients. 
4. Cancer 
5. P-glycoprotein: multidrug efflux pump that hampers absorption of drugs. 
6. Cytochrome P450: enzymatic complex involved in metabolism of xenobiotics. 
7. Paclitaxel: anticancer agent with very poor oral bioavailability. 
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Introduction 
Oncology is one of the few areas of medicine where the large majority of patients 
are treated intravenously (iv) rather than orally. Although oral chemotherapeutic 
agents have been available for the last 50 years, and currently 10% of cancer 
chemotherapy is prescribed to patients by means of an oral formulation, doubts on 
efficacy and limited interest of pharmaceutical companies have hampered their 
use. The development and approval for clinical use of new oral anticancer agents 
will probably change in the near future. By 2013, this percentage is predicted to 
increase by 25% [1]. 
In the past, anticancer therapies were mainly focused on parenteral drug delivery 
because the goal was to deliver the maximum tolerated dose of drug to optimize 
cell kill in a single episode, followed by a free-drug several week period to allow 
bone marrow recovery [2].  
Convenience and easiness of administration make oral chemotherapy an attractive 
option [3, 4]. It is also especially appropriate where prolonged drug exposure is 
desirable [5] and also allows the replacement of drugs that require protracted 
administration periods. It avoids complications and costs derived from intravenous 
chemotherapy, while maintaining the patients' quality of life [6]. From the economic 
standpoint, oral administration is more attractive because it reduces the cost for 
hospitalization and infusion equipment supplies [7], what makes it a “dominant 
strategy” in pharmacoeconomic terms [6].  Furthermore, oral chemotherapy is 
particularly attractive as cancer is becoming a chronic disease for an increasing 
number of patients [8]. 
However, the oral administration of cancer drugs also possesses challenges. One 
of them involves time to train patients in addition to remaining uncertainty about 
their compliance [1]. Another major challenge is the low and variable bioavailability 
of many drugs after oral administration, due to factors such as rapid degradation, 
limited solubility, poor permeability or extensive pre-systemic metabolism [9]. 
Indeed, efflux by P-glycoprotein (Pgp) and/or intestinal and hepatic metabolism by 
cytochrome P450 (CYP450) metabolizing enzyme system have frequently been 
classified as limitant factors of oral bioavailability of common anticancer drugs [10]. 
Currently, the use of nanocarriers has been proposed to improve the 
gastrointestinal bioavailability of drugs with poor oral bioavailability. Nanocarriers 
improve the solubility of poorly soluble drugs and the diffusion of the drug within 
the mucus, enhancing the availability for the drug to be absorbed through the 
gastrointestinal epithelium or lymphatic transport. In some cases, nanocarriers 
have also increased the drug permeability across the intestinal barrier. As a matter 
of fact, several pharmaceutical excipients have shown activity to inhibit pre-
systemic metabolism produced by CYP450 [11] and/or Pgp efflux pumps located in 
the enterocytes [12, 13]. 
This review focuses on the use of cyclodextrins alone or in conjunction with 
nanoparticles for oral delivery of drugs. Classical cyclodextrin-drug complexes can 
enhance the oral absorption of drugs by virtue of their solubilizing properties [14]. 
Their association with bioadhesive nanoparticles can further facilitate the 
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bioavailability of encapsulated drugs by increasing the intestinal permeability of the 
drug. The state-of-the-art technology and challenges in this area are discussed.  
 
Cyclodextrins 
Cyclodextrins (CDs) were first described in 1891 by Villiers when he studied the 
bacterial digestion of starch [15, 16]. Villiers described this substance as some kind 
of cellulose, which he called “cellulosine”. Years later, Franz Schardinger isolated 
Bacillus macerans and observed the production of 2 different crystalline structures 
when the microorganism was grown on a starch-containing medium. Observing 
similar properties to the degradation products of starch, he named them α-, and β-
dextrin [17]. Later Freudenberg and his co-workers elucidated the cyclic structure 
of these two dextrins and described the main physicochemical properties and their 
abilities to form complexes [18]. Thus, these compounds were then named, as they 
are known nowadays, cyclodextrins: α-cyclodextrins (α-CD) and β-cyclodextrins (β-
CD). In 1948–1950, the γ-cyclodextrin (γ-CD) was discovered and its structure 
elucidated.  The structure, physicohemical properties, inclusion complex forming 
abilities and the industrial obtention of cyclodextrins were figured out by the end of 
1960s. In the 1970s, improvements were performed in the biotechnological areas 
increasing the production of cyclodextrins by the enzymatic degradation of starch 
and the production of different derivatives for different applications. 
Cyclodextrins are crystalline cyclic oligosaccharides containing six, seven or eight 
(α-1,4) linked α-D-glucopyranose units with amphiphilic properties and a shape of a 
truncated cone or “bucket” [19, 20]. Cyclodextrins are named depending on the 
number of glucopyranose units. Major and industrially produced cyclodextrins are 
named as follows: α-cyclodextrin possessing six units, ß-cyclodextrin possessing 
seven units and γ-cyclodextrin possessing eight units. The β-cyclodextrin family is 
the most commonly used cyclodextrin. Cyclodextrins are characterized by 2 flat 
faces in their structure: the upper face or rim and the lower face or rim. The upper 
rim corresponds to the wider part of the truncated cone structure, while the lower 
rim refers to the narrow part of the molecule. Generally, the upper rim and the 
lower rim are also referref to as the secondary and the primary faces, respectively. 
Regarding their structure, the external surface is hydrophilic whereas the internal 
cavity is lipophilic. This central moiety is formed by the skeletal carbons, hydrogen 
atoms and glycosidic oxygen atoms of the glucose structure conferring the 
lipophilic characteristics [21-23]. On the other hand, the external surface is 
hydrophilic due to the presence of secondary hydroxyl groups at the wide edge of 
the structure and primary hydroxyl groups at the narrow edge.  
These natural cyclodextrins form total or partial inclusion complexes with active 
molecules. This combination CD-drug alters the water solubility, stability, 
diminishes side effects and promotes compatibility of drugs with other drugs or 
excipients, as well as ameliorate patient compliance by taste masking [23-25]. 
However, natural cyclodextrins show some drawbacks such as poor versatility, 
limited aqueous solubility (β-cyclodextrin) and toxicological limitations. In fact, two 
of the natural cyclodextrins are known to be parenterally unsafe due to nephrotoxic 
effects [26]. The exact mechanism of the nephrotoxicity of α- and ß-cyclodextrins is 
  6
unknown, but it is believed to be related to either cyclodextrin uptake by kidney 
tubular cells resulting in disruption of intracellular function, or the extraction of lipid 
membrane components by the cyclodextrins [16, 27]. 
For these reasons, natural cyclodextrins have been chemically modified in order to 
achieve one or more of the following goals: alter their water solubility, reduce the 
nephrotoxicity and hemolysis encountered on iv administration, ameliorate the 
interaction with biological membranes and provide controlled drug release profiles. 
For these purposes, substitution of the hydrogen bonds of these natural CDs by 
hydroxyl, methoxy or other alkyl groups improves significantly the aqueous 
solubility of the compounds. Some of these modified CDs are: hydroxypropyl-β-
cyclodextrin (HPβCD), sulfobuthylether-β-cyclodextrin (SBEβCD) and the randomly 
methylated derivatives (MβCD) such as dimethyl-β-cyclodextrin (DMβCD). Table 1 
summarises some of the most useful derivatives based on β-cyclodextrin. 
 
Table 1 
 
Today, cyclodextrins are considered as useful excipients widely spread in 
pharmaceutical applications. Among other reasons, cyclodextrins may be used as 
complexing agents since they can alter the water solubility and therefore, stability 
of poorly water-soluble drugs. Thus, by the oral route, the effect of cyclodextrins 
may improve the oral bioavailability of lipophilic compounds. Cyclodextrins interact 
with specific components of the membranes but are rarely absorbed from the 
gastrointestinal tract. Furthermore, natural CDs (α-, β- and γ-cyclodextrins) cannot 
be hydrolyzed by human salivary and pancreatic amylases [28]. Nonetheless, they 
can be fermented by intestinal microflora. In addition, cyclodextrins may reduce the 
irritation (a big number of drugs are irritant for the mucus layer of the 
gastrointestinal tract), they may control the release of the drug from the inclusion 
complex, prevent or minimize interactions and mask unpleasant tastes [29]. Finally 
it is also important that, in general, cyclodextrins are not toxic, because of the lack 
of absorption from the gastrointestinal tract when administered orally [28].  
Parallel to this, cyclodextrins have also been under investigation for their 
capabilities to disturb the activity of the Pgp and CYP450 as well as for their 
incorporation into or formation of nanoparticulate drug delivery systems. 
Nanoparticles are of pharmaceutical interest because of their active and passive 
targeting properties and their ability to deliver poorly available drugs.  
 
Cyclodextrins as solubilising agents 
The most extended mechanism by which CDs increase the apparent solubility of 
poorly water-soluble drugs is the inclusion complex formation. These complexes 
imply dynamic equilibrium between the molecules involved, the guest and host 
molecules and the complex [16, 30]. The increased apparent solubility can enable 
solution-based dosage forms such as oral liquids. Moreover, according to the 
Whitney equation, increasing the apparent solubility of a drug can increase drug 
dissolution rate and as a consequence, a rise in the oral bioavailability of the drug 
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for compounds with limited oral bioavailability caused mainly by its low solubility or 
dissolution rate [31, 32].  
A useful approach in assessing where CDs can be applied in this context is the 
Biopharmaceutical Classification System (BCS).  In consonance with the BCS, 
drugs can be split into 4 categories based on their aqueous solubility and 
permeability properties [33, 34]. Class I includes those compounds with both 
soluble and permeable properties and with an oral bioavailability which may only 
be limited by the rate at which they reach appropriate sites of absorption in the 
gastrointestinal tract. Class II drugs (poor solubility, high permeability) are 
compounds with a limited oral absorption due to drug solubility and dissolution rate. 
Class III compounds (high solubility, poor permeability) show oral bioavailability 
limited by the barrier properties of the gastrointestinal tract. Finally, Class IV 
compounds (low solubility and permeability) combine the limitations of both Class II 
and III materials. Thus, the use of cyclodextrins may be of main interest to solve 
the problems associated with Class II and IV compounds. Concerning drugs 
included in Class IV, it has recently been described that cyclodextrins can act as 
enhancers of the oral permeability of drugs (see the following section). In any case, 
the alteration of the properties of drugs included in these classes implies changes 
such that they become Class I-like in behavior [35, 36]. 
There are different ways by which the cyclodextrin interacts with the drug. The 
central CD cavity provides a lipophilic microenvironment into which suitably sized 
drug molecules may enter and be included. Then, no formal bonds are formed, 
stabilizing the system CD-drug by means of dispersion forces. However, the 
interaction implies a dynamic equilibrium between both molecules [37]. The result 
of these interactions is the increase of the apparent solubility of the drug. These 
interactions are relatively weak so as to permit the equilibrium of free drug 
molecules and cyclodextrins [16, 30]. The ability of the host molecule, cyclodextrin, 
to form complexes with the guest molecule depends on two factors: (i) the size of 
the guest molecule and (ii) the thermodynamic interactions between all the 
components (cyclodextrin, guest molecule, solvents). In all cases, the guest 
molecules should be of the appropriate size to fit in the cavity and the interactions 
should be favourable energetically.  
The most common stoichiometry of drug/cyclodextrin complexes is 1:1, i.e. one 
drug molecule forms a complex with one cyclodextrin molecule [35]. In fact, studies 
carried out by several research groups have demonstrated that cyclodextrins form 
both inclusion and non-inclusion complexes, which can coexist in aqueous 
solutions. Furthermore, they tend to form aggregates, capable of solubilizing 
hydrophobic molecules through micellar-type mechanism [35, 36, 38]. 
Worldwide, more than 30 different drugs are currently marketed as solid or 
solution-based CD complex formulations (Table 2) [35, 39]. In these 
pharmaceutical products, CDs are mainly used as complexing agents to increase 
the aqueous solubility of poorly water-soluble drugs and, thus, their bioavailability 
and stability [40-42].  
 
Table 2 
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Concerning anticancer drugs, some of them are ascribed to Classes II and IV of 
the BCS and show limited possibilities to be administered by oral route [43]. In this 
context, different anticancer drugs have been studied including paclitaxel [44], 
danazol [45], noscapine [46] or exemestane [47, 48]. 
One of the first studies was conducted by Kikuchi and collaborators in 1987. In this 
study, carmofur (a derivative of 5-fluorouracil) was complexed with ß-cyclodextrin, 
DMßCD or trimethyl-ß-cyclodextrin (TMβCD). When orally administered to 
laboratory animals, the resulting AUCs for the drug-cyclodextrin complexes were 
up to 7-times that found for the control formulation of carmofur [49]. Later, Cserhàti 
and Holló studied the interaction between 23 anticancer drugs and HPβCD and 
concluded that the formation of an inclusion complex may influence differently the 
biological effect of individual anticancer drugs and, thus, result in modified 
effectivity [44].  
More recently, Piette and co-workers evaluated the oral bioavailability of Ro 28-
2653 after dissolution in water by means of complexation with HPβCD. The Ro 28-
2653/HPβCD oral solution was compared to a typical suspension of this drug in an 
aqueous solution of wetting and viscosifying agents. Both formulations were 
administered orally to sheep at a dose of 15 mg/kg. The absolute bioavailability 
was significantly higher with the solution (80%) than with the suspension (8%) [50]. 
Similarly, Yavuz and collaborators prepared inclusion complexes between 
exemestane (EXE) and MCD, HPCD or HPCD [47]. The complexes between 
EXE and MβCD displayed a high ability to increase the permeability of the 
anticancer drug to cross biological membranes. This fact appeared to be due to the 
capability of this cyclodextrin to interact with the lipids and, then, perturb the 
membrane integrity [51]. 
 
Cyclodextrins as P-glycoprotein and cytochrome P450 selective inhibitors 
P-glycoprotein is a transmembrane protein responsible for the transport of a wide 
range of chemicals and hydrophobic molecules, such as chemotherapeutics, 
steroidal hormones or immunosuppressive agents. It belongs to the family of the 
ATP-binding cassettes (ABC) transporters and needs energy of the hydrolysis of 
ATP to function. Pgp is highly expressed, especially in the small intestinal epithelial 
cells where it works as an efflux pump, preventing the absorption of different drugs 
and molecules and avoiding the entrance of these molecules to the blood stream 
[52]. Pgp may be involved in the relocation of cholesterol from cytosol to the 
plasmatic membrane and in the stabilization of the cholesterol-rich domains [53]. 
On the other hand, cytochrome P450 is a metabolic enzyme in charge of the 
oxidation of different compounds as well as the conversion of highly lipophilic drugs 
in more water soluble forms in order to facilitate their excretion from the body. 
CYP450 is a big family of enzymes present all through the gastrointestinal tract 
and therefore, along with Pgp, both are responsible for the low oral bioavailability 
of many anticancer drugs. 
Cyclodextrins have been reported to act as inhibitors of the Pgp [53] and the 
CYP450 [54]. Different hydrophilic CD derivatives interact with the cholesterol units 
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of the membrane resulting in a depletion of these domains and therefore, decrease 
the ATPase activity and subsequently, the action of the efflux pumps [55]. A 
schematic representation of this effect is shown in Figure 1.  
 
Figure 1 
 
These properties of CDs have been described previously by different groups, who 
reported evidence of the appreciable interaction of CDs with cell membranes and 
their components. Thus, Arima and co-workers reported the effects of the 
combination of DMβCD and tacrolimus on the oral bioavailability of this Class II 
compound [56].Their work demonstrated that the enhancing effect of DMβCD on 
the oral bioavailability of tacrolimus was not only due to the solubilizing effect of CD 
but also, at least in part, to the inhibitory effect of the CD on the Pgp mediated 
efflux in the gastrointestinal tract. The DMβCD showed an interaction with the 
membrane components, i.e. cholesterol and phospholipids. They concluded that 
the mechanism by which DMβCD inhibits Pgp is different than that of the typical 
Pgp selective inhibitors (cyclosporin A or verapamil). DMβCD is not a substrate of 
the Pgp and apparently, allows the release of the protein from the membrane of 
Caco-2 cells. Their findings were in correlation with those of Pathak and coworkers 
[57], who studied the complexation of saquinavir, an HIV protease inhibitor also 
ascribed to the Class IV of the BCS, with methyl-beta-cyclodextrin. Their results 
indicated an improvement of the pharmacokinetic profile of saquinavir and enhance 
the oral absorption of the drug by the complexing with the CD which showed a 
similar behavior to that reported for other methylated cyclodextrins. In all cases, the 
main studied cyclodextrins were the methylated types.  
Fenyvesi and co-workers have carried out different experiments with different 
cyclodextrins, mainly focused on the MβCD. They studied the effect of the CDs 
combined with Taxol® on Caco-2 model. CDs were capable of removing 
cholesterol from the structure of the membrane and change its physicochemical 
properties, permeability, and fluidity and in addition, modulate the action of the Pgp 
efflux pump, resulting in a higher permeability for Taxol® (trademark of paclitaxel). 
CDs altered the lipid packing of the membrane leading to changes in the 
disposition of the components of the lipid bilayer, especially cholesterol and 
phospholipids, affecting to the transport functions [58].  
Regarding the effect of CDs on CYP450, Ishikawa and collaborators reported the 
interactions of HPβCD and MβCD, on different hepatic isoforms of CYP450. In 
their studies, the concentration of cyclodextrin present had a different effect on the 
activity of the isoforms. In some of the studied isoforms, the enzymatic activity was 
increased or even reduced and in some cases the induction period was altered. 
While the HPβCD did not have the same effect on the isoforms studied (the 
HPβCD influenced on the isoforms CYP2C19 and CYP3A4), the MβCD inhibited, 
in all cases, the metabolism, specifically at high concentrations [54].  
 
 
Cyclodextrin nanoparticles 
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Some types of cyclodextrins, apart from their ability to form inclusion complexes, 
show self-alignment properties and the ability in aqueous media to form 
nanoparticles spontaneously without the presence of a surfactant [59, 60]. These 
oligosaccharides are amphiphilic and, initially, they were synthetised (i) to enhance 
the interaction with biological membranes and (ii) to improve the interaction with 
hydrophobic drugs by creating a second zone of attraction other than the 
cyclodextrin cavity [61-63]. 
Amphiphilic cyclodextrins are generally classified according to their surface charge 
as follows: non-ionic, cationic and anionic amphiphilic cyclodextrins. The non-ionic 
amphiphilic cyclodextrins are obtained by grafting aliphatic chains of different 
length onto the primary and/or secondary face of the CD main glucopyranose unit. 
Among others, the main types of these oligosaccharides are known as lollipop, 
cup-and-ball, medusa-like, skirt-shaped, bouquet-shaped and cholesteryl 
cyclodextrins. More recently, cationic amphiphilic cyclodextrins characterized by 
the presence of amino groups were synthesised. A series of polyamino-β-
cyclodextrins have been reported [65] with complete substitution by amine groups 
at the position 6. Finally, anionic amphiphilic cyclodextrins usually contain a sulfate 
group that renders anionic properties to their structure. An efficient synthetic route 
to obtain acyl-sulfated-β-cyclodextrins has been introduced in which the upper rim 
is functionalized with sulfates and the lower rim with fatty acid esters. Other types 
of anionic amphiphilic cyclodextrins are the fluorine and the fluorophilic 
cyclodextrins. Table 3 gives some information about all these oligosaccharides (an 
interesting review about these amphiphilic cyclodextrins was recently written by 
Bilensoy and Hincal [64]). 
 
Table 3 
 
Cyclodextrin nanoparticles are usually prepared by nanoprecipitation [66, 67], 
emulsion/solvent evaporation [68] or detergent removal technique [69]. Drug 
loading into nanoparticles is governed by the loading technique used. Three main 
strategies are used in order to load the drug into the cyclodextrin nanoparticles: (i) 
use of pre-formed drug:amphiphilic cyclodextrin complexes; (ii) incubation between 
amphiphilic cyclodextrins and drug in the same solvent prior to the formation of 
nanoparticles; and (iii) preparation of nanoparticles directly from pre-formed 
drug:amphiphilic cyclodextrin complexes and loaded further by the addition of 
excess drug solution in the organic phase [70, 71]. 
Nanoparticles prepared from non-ionic amphiphilic cyclodextrins have been loaded 
with different anticancer agents with bioavailability problems, such as tamoxifen 
citrate, paclitaxel and camptothecin. Tamoxifen, an antiestrogen drug used for the 
first-line and adjuvant therapy for metastatic breast cancer, has been incorporated 
into the β-CDC6 amphiphilic cyclodextrin nanoparticles. The idea was to reduce 
the severe side effects associated to the non-selective dose-dependent cytotoxicity 
of tamoxifen during long-term chemotherapy. Tamoxifen citrate-loaded 
nanoparticles released the drug in a controlled way up to 6 h [63]. Anticancer 
efficacy of tamoxifen-loaded nanoparticles was demonstrated to be equivalent to a 
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control solution of the anticancer drug in ethanol against MCF-7 human breast 
cancer cells. In addition, the transcription efficiency of the tamoxifen-amphiphilic 
cyclodextrin nanoparticles was evaluated against MELN cells in the presence of 
17-β-estradiol (E2) for the inhibition of E2-mediated luciferase gene expression and 
demonstrated concentration-dependent transcription efficiency [72]. 
More recently, cyclodextrin nanoparticles prepared from amphiphilic β-cyclodextrin 
modified on the primary face with 6C aliphatic esters (6-O-CAPRO-β-CD) were 
used to load paclitaxel [73]. The resulting nanoparticles were evaluated for their 
safety and efficacy. Paclitaxel-loaded amphiphilic cyclodextrin nanoparticles were 
found to be physically stable for a period of 1 month [74]. In addition, nanoparticles 
significantly reduced the hemolytic properties caused by commercial vehicle 
(Cremophor EL). Paclitaxel-loaded amphiphilic nanoparticles demonstrated similar 
anticancer efficacy against MCF-7 cells when compared to paclitaxel solution in the 
Cremophor vehicle [74]. 
Another potent anticancer drug, camptothecin, which is reported to be clinically 
problematic due to its conversion from its active lactone form to its inactive 
carboxylate form under physiological conditions, was formulated using two different 
amphiphilic β-cyclodextrins: β-CDC6 and 6-O-CAPRO-β-CD. Cyclodextrin 
nanoparticles have succeeded in maintaining camptothecin in its active lactone 
form with considerable loading values and release profiles prolonged up to 96 h 
[75]. This study is significative because amphiphilic cyclodextrin nanoparticles 
displayed a superior efficiency for drug loading (which was 4 to 6-fold higher) than 
poly(lactic-co-glycolic acid) [PLGA] or poly(ε-caprolactone) [PCL] nanoparticles’ 
loading values. In addition, these amphiphilic cyclodextrin nanoparticles displayed 
prolonged release profiles for camptothecin, with β-CDC6 having a release period 
of up to 6 days and 6-O-CAPRO-β-CD releasing the drug within a 14-day period, 
whereas both PLGA and PCL nanoparticles released the drug completely within 48 
h [75]. In vivo, 6-O-CAPRO-β-CD nanoparticles displayed a significantly higher 
survival rate in a rat glioma model than the other types of nanoparticles [76]. 
Non-ionic amphiphilic cyclodextrins modified with 16C aliphatic chains linked with 
thiol bonds have also been used to form nanoparticles for docetaxel delivery. 
When Hep-2 cells were exposed to free docetaxel and docetaxel incorporated in 
these cyclodextrin nanoparticles, significantly higher cell damage and cell death 
were observed for nanoparticle-associated docetaxel [77].  
Cationic amphiphilic nanoparticles, from heptakis(2-amino-O-oligo(ethylene oxide)-
hexylthio-β-CD, have been used to encapsulate anionic porphyrins. These 
nanoparticles preserved the photodynamic properties of the entrapped photoactive 
agent in studies with tumor HeLa cervical carcinoma cells [78]. On the other hand, 
nanoparticles from cationic cyclodextrins have shown a great ability to bind 
nucleotides and enhance delivery by viral vectors. The main advantage of 
polycationic cyclodextrins and their nanoparticles is their enhanced ability to 
interact with nucleic acids and act as non viral vectors for gene therapy [65]. 
 
 
Combination between cyclodextrins and polymer nanoparticles  
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In spite of the different developments in progress with amphiphiphilic nanoparticles, 
to date, the majority of these studies have been designed for parenteral 
administration rather than for oral treatment. Furthermore, information regarding 
the behavior of these carriers for the oral delivery of anticancer drugs is very 
scarce. At this point, it is interesting to remember that some of the anticancer drugs 
with interest for oral delivery are included in the class IV of the BCS and, in the last 
years, a number of strategies have been proposed to promote the oral 
bioavailability of these therapeutic agents.  
One interesting approach would consist on the combination of a Pgp and/or 
cythochome P450 inhibitors with bioadhesive polymer nanoparticles (as drug 
carriers) containing the drug sensitive to the action of these physiological 
processes. In the past, Pgp and/or CYP450 inhibitors such as verapamil [79], 
cyclosporine A [80] or their analogues [81-83] have been proposed. However, most 
of them have difficulties in formulation of their own and the use of these drugs may 
be limited in humans, especially for repeated administrations. For these reasons an 
interesting variation in this approach may be the use of pharmaceutical excipients 
showing moderate inhibition or disruptive properties of the Pgp and/or the 
cytochrome P450 (i.e. cyclodextrins). 
On the other hand, bioadhesive nanoparticles offer a number of advantages 
related to their capability to be immobilised at the surface of the gut mucosa. The 
adhesive phenomenon may slow the particle transit time through the 
gastrointestinal tract, thereby enhancing the time scale for drug absorption [84]. In 
addition, this class of colloidal drug carriers can protect the loaded drug from its 
eventual inactivation or degradation by the pH conditions or enzymes, interact with 
the mucosa and prolong the contact time with the membrane, where the absorption 
occurs [84, 85]. The intensity of this interaction phenomenon between these drug 
carriers and the mucosa is influenced by the stability of the nanoparticles as well 
as their size and surface characteristics [84, 86, 87]. Among others, a number of 
polymers and macromolecules have been reported as adequate materials to 
prepare this type of nanoparticles, including chitosan [88, 89], poly(lactic acid) 
(PLA) [90], gliadin [91] and poly (methyl vinyl ether-co-maleic anhydride) [92].  
Thus, the idea would be to use nanoparticles with improved bioadhesive properties 
capable of loading the drug and the cyclodextrin. These vehicles would travel 
through the gastrointestinal tract up to the surface of the mucosa where they would 
release their content. Then, the inhibitory effect of the cyclodextrins on the activity 
of the Pgp and the cytochrome P450 would facilitate the oral absorption of the 
anticancer drug. Figure 2 shows a diagram summarizing this idea. For a maximum 
of efficiency of the pharmaceutical device, the bioadhesive nanoparticles should 
develop the adhesive interactions with the surface of the enterocytes rather than 
the mucus layer covering the gut mucosa. In fact, different reports have suggested 
that the mucosal administration of particulates concluded with the particles trapped 
in the mucus layer lining and protecting the mucosa formed by the epithelial cells 
rather than attached to or internalized by intestinal cells [93-95]. This lack of 
particle entry into mucosal epithelia has been long attributed to inefficient 
penetration through the mucus layer. Since nanoparticles are mainly bound to the 
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mucus layer through interactions with mucin fibers, the transit time of these 
systems would be determined by the physiological turnover time of the mucus 
layer. In addition, the release of the cyclodextrin and the drug in a relatively remote 
area of the enterocyte surface may hamper the drug absorption.  
 
Figure 2 
 
Recently, this strategy was validated by using poly(anhydride) nanoparticles based 
on the copolymer of methylvinylether and maleic anhydride (Gantrez AN from Isp. 
Corp.). These nanoparticles are easily prepared by a desolvation method and the 
resulting carriers are capable of developing bioadhesive interactions within the gut 
[96]. More importantly, the surface of these poly(anhydride) nanoparticles can be 
easily modified by simple incubation with different excipients or ligands including 
mannosamine [97], thiamine [98] or chitosan [99] in order to modify their fate within 
the gastrointestinal tract. In this way, the incorporation of cyclodextrins into these 
poly(anhydride) nanoparticles facilitates their diffusion across the mucus layer and  
as a consequence, the mean residence time of the nanoparticles adhered to the 
intestinal gut mucosa is significantly higher than for conventional nanoparticles 
[100]. The distribution in the gut of these cyclodextrin-poly(anhydride) 
nanoparticles was confirmed after radiolabeling of these nanoparticles with 
technetium. It was observed that, after oral administration, nanoparticles remained 
in the stomach during the first hour. Then, they were slowly discharged in the small 
intestine and continued to move along the gut during the time of the experiment 
[101]. From fluorescence microscopy visualization studies, cyclodextrin-
poly(anhydride) nanoparticles were found broadly and homogeneously distributed 
along the ileum mucosa (mucus layer and surface of the enterocytes) whereas 
conventional nanoparticles were mainly found in the mucus layer of the ileum 
[100]. In any case, no evidence of translocation or distribution to other organs of 
the body of animals was observed for these cyclodextrin-poly(anhydride) 
nanoparticles. 
Recently, this strategy of combination between cyclodextrins and bioadhesive 
nanoparticles has demonstrated effectiveness in improving significantly the oral 
bioavailability of paclitaxel [102]. This anticancer drug is widely used in clinic for the 
treatment of several carcinomas including breast [103], advanced ovarian [104], 
non small cell lung [105] and colon [106]. By the oral route, it shows a very low 
bioavailability, which is caused by several factors. Firstly, paclitaxel is a highly 
hydrophobic molecule with a poor aqueous solubility and a very low dissolution 
rate in biological media [107]. Secondly, paclitaxel is a good substrate for the 
multidrug efflux pump Pgp [83] and shows a high affinity for the intestinal 
cytochrome P450 (i.e. CYP3A4) metabolic enzymes [10].  
In these carriers, cyclodextrins have been used with a double purpose: as 
solubilising agents of paclitaxel, which it is an extremely lipophilic compound, and 
for the capability of these oligosaccharides to disturb and inhibit the activity of the 
intestinal P-glycoprotein (see Section “Cyclodextrins as P-glycoprotein and 
cytochrome P450 selective inhibitors”). 
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Paclitaxel was incorporated into nanoparticles as complex with different types of 
cyclodextrins. This strategy was used by Monza da Silveira and co-workers to 
increase the loading of poly(alkylcyanoacrylate) nanoparticles with various 
lipophilic drugs and to modify drug release [108]. In our case, the paclitaxel loading 
was found to be dependent on the type of cyclodextrin used. Thus, when 
complexes were formed with either β-CD or HPβCD the drug loading was about 4 
and 17%, respectively, whereas in the absence of oligosaccharide the paclitaxel 
loading in poly(anhydride) nanoparticles was only 0.03% [109]. Another possibility 
to incorporate the drug into nanoparticles may be its incubation with the 
cyclodextrin and the polymer prior to formation of nanoparticles [110]. 
Nevertheless, this formation of drug-cyclodextrin complex “in situ” yields, in 
general, low drug loading values. 
Once nanoparticles were orally administered to laboratory animals, the paclitaxel 
plasma levels were maintained through time from Tmax up to 24 hours post-
administration, characterized by a plateau close to Cmax. These sustained levels of 
paclitaxel implied a relative oral bioavailability of about 80% [102]. The increase of 
the relative oral bioavailability would be a result of the combination of the 
bioadhesive and inhibitory properties of these cyclodextrin-poly(anhydride) 
nanoparticles. In fact, nanoparticles would efficiently approach the PTX-
cyclodextrin complexes to the surface of the enterocytes. Here, the nanocarriers 
would be immobilised in the absorptive membrane and progressively, release their 
content. Subsequently, the dissociation of the complexes would occur resulting in 
the free paclitaxel and the oligosaccharide. Finally, the anticancer agent would be 
rapidly absorbed while the CDs would disturb the normal activities of the P-gp and 
CYP450, by interaction with the lipid bilayer at the gut mucosa. Interestingly, the 
oral administration of the drug-cyclodextrin complexes alone or in physical mixture 
with empty nanoparticles was unable to promote the permeability of paclitaxel as 
well as its oral bioavailability (Figure 2) [102, 109]. 
Also recently, copolymers obtained by the polymerization of cyclodextrin with 
“pharmaceutical” monomers (i.e. lactic and glycolic acids) have been obtained and 
proposed for the preparation of biodegradable nanoparticles. Thus, PLGA-βCD 
copolymer was synthesized by reacting L-lactide, glycolide, and β-cyclodextrin in 
the presence of stannous octoate as a catalyst. Nanoparticles can be obtained by 
a relatively simple double emulsion method and the resulting carriers displayed 
high doxorubicin loadings as well as adequate in vitro release profiles for 
anticancer therapy [111]. In the same way, Wang and collaborators synthesized a 
novel biodegradable and amphiphilic copolymer composed of hydroxypropyl-β-
cyclodextrin, polylactide, and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine. 
Nanoparticles from this copolymer loaded with doxorubicin demonstrated an 
antitumor activity against cancer HepG2 and A549 cells comparable to that 
observed with the free drug [112]. 
 
Future Perspective 
The oral route is perhaps the preferred route for drug administration thanks to 
patient convenience and compliance. Still, in a number of cases, factors such as 
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rapid degradation, low solubility, poor permeability or significant pre-systemic 
metabolism reduce the oral bioavailability. It is well known that the drug, prior to 
absorption through the epithelial cells, has to be sufficiently and rapidly dissolved in 
the aqueous fluids of the gastrointestinal tract. Poor dissolution properties, as 
observed for lipophilic molecules, may importantly hamper the fraction of drug 
absorbed. On the other hand, the permeability of a molecule may be negatively 
affected when the drug is characterised by the presence of hydrophilic or ionisable 
groups in its chemical structure. Similarly, this permeability is also low when the 
drug is substrate of the efflux transport systems which are found in the surface of 
enterocytes. The sensibility to the severe conditions of the gut is another negative 
factor affecting the bioavailability of a molecule as well as its degradation by 
luminal enzymes or enzymatic complex located in either the enterocytes (pre-
systemic metabolism) or the liver (first-pass metabolism). In all cases, overcoming 
these hurdles is the major challenge for the development of oral therapies including 
oral chemotherapy. 
A number of antineoplastic drugs are characterized by unfavorable 
physicochemical properties in tandem with an important sensitivity by the 
physiological mechanisms of detoxification. These facts limit the possibilities to 
develop oral formulations and treatments. However, oral chemotherapy is attractive 
because it improves patients’ comfort. In addition, it would also be adequate where 
prolonged drug exposure is preferable. Currently, many anticancer therapies are 
cytostatic and thus, are more effective if chronic and continuous tumor exposure is 
achieved. This mechanism of action virtually requires oral daily and prolonged 
therapies.  
In order to solve these drawbacks a number of strategies have been developed. 
One of them is based on the use of cyclodextrins. These pharmaceutical excipients 
offer a number of advantages interesting to solve both the low solubility and low 
permeability problems characterizing a considerable number of molecules. Thus, 
cyclodextrins are able to form host-guest complexes with hydrophobic molecules 
permitting, as a result, increase their aqueous solubility. In addition, the disturbing 
effect of these oligosaccharides in both the activity of the intestinal P-glycoprotein 
extrusion pump and the cythocrome P-450 enzymatic complex may dramatically 
increase the permeability of a pre-systemic metabolized drug. Nevertheless, and in 
contrast to the solubilizing effect, this enhancement of the intestinal permeability by 
cyclodextrin “encapsulation” is not found in vivo. This fact may be attributed to the 
specific conditions that are usually found in the gastrointestinal tract such as 
presence of high volume of liquids, peristaltism and the presence of the protective 
mucus layer on the absorptive membrane. In order to solve these inconveniences, 
one possible solution could be the combination of cyclodextrins with bioadhesive 
nanoparticles capable of developing adhesive interactions with components of the 
gut mucosa. The idea is that the bioadhesive nanoparticles would transport the 
drug–cyclodextrin complexes till the surface of the mucosa where they would be 
released. Then, the inhibitory effect of the cyclodextrins on the activity of the Pgp 
and the cytochrome P450 would facilitate the oral absorption of the loaded drug. 
This strategy has been validated with paclitaxel (and other drugs such as 
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cyclosporine A and atovaquone). The resulting pharmaceutical device 
demonstrated the viability of such approach and the capability of these 
cyclodextrin-polymer nanoparticle vehicles to significantly increase the oral 
bioavailability of this anticancer drug (about 80% in rat) and, more importantly, to 
offer sustained and prolonged blood levels of paclitaxel for at least 24 hours. 
Another attractive strategy that could be applied is the combination of liposomes 
and cyclodextrin complexes [131-132]. Although work has been published related 
to liposomes and oral administration of certain drugs (i.e. anti-inflammatory agents 
or anti-histamines), little evidence there is for anticancer agents complexed with 
cyclodextrins and encapsulated in liposomes for their oral delivery. Herein, the 
development of these systems should be further investigated since they could offer 
a potential delivery system in the near future. 
Although further studies are necessary, the technology and devices capable of 
offering effective oral delivery of anticancer drugs with both poor characteristics of 
solubility and permeability is feasible. In the close future, these carriers may 
facilitate the implementation of chronic cancer treatments. Nevertheless, at this 
moment, no strategy is able to target a drug specifically to distant cancer cells after 
oral administration. This goal remains a challenge for the future.  
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Executive summary 
Applications of cyclodextrins 
Cyclodextrins are pharmaceutical ingredients that may improve the aqueous 
solubility of lipophilic drugs. As a consequence, the resulting inclusion complex 
may control the release of the drug and increase the oral bioavailability of the 
active ingredient. 
Cyclodextrins disturb and inhibit the activity of the intestinal P-glycoprotein and the 
cytochrome P450 and, thus, may modify the permeability of drugs. However, in 
vivo, this effect is no significant. 
 
Applications of bioadhesive nanoparticles 
Bioadhesive nanoparticles can protect the loaded drug from its eventual 
inactivation or degradation in the harsh conditions of the gut. In addition, due to 
their polymer nature, they can control the release of the loaded drug. 
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Bioadhesive nanoparticles can interact with the gut mucosa and prolong the 
contact time with the membrane where the absorption occurs. 
 
Combination of cyclodextrins and bioadhesive nanoparticles 
The association of cyclodextrins to polymer nanoparticles permits to increase the 
drug loading of lipophilic compounds.  
This combination between cyclodextrins and bioadhesive nanoparticles yields 
pharmaceutical vehicles capable to increase the intestinal permeability of paclitaxel 
(a class IV compound with a very low oral bioavailability) and, as a consequence, 
offer a relative oral bioavailability close to 80%. 
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Table 1. Some of the most common derivatives based on βCD.  
  Derivate Characteristics Ref. 
Hydrophilic 
derivates 
Methylated 2,6-di-O-methyl-βCD per-O-methyl-βCD 
Soluble in cold water and 
organic solvents. Pgp 
inhibitory activity. 
Hemolytic. 
[28, 
53, 
56, 
113] 
Hydroxyalkylated 
2-hydroxypropyl-βCD 
3-hydroxypropyl-βCD 
2,3-hydroxypropyl-
βCD 
Amorphous mixture of 
different degrees of 
substitution. Highly water-
soluble, low toxicity. 
[28, 
114] 
Branched 
Glycosyl-βCD 
Maltosyl-βCD 
Glucuronyl-glucosyl-
βCD 
Highly water-soluble, low 
toxicity. 
[20, 
28, 
114] 
Hydrophobic 
derivates Alkylated 
2,6-di-O-ethyl-βCD 
per-O-ethyl-βCD 
Poorly water-soluble, 
soluble in organic 
solvents, Pgp inhibitory 
activity. 
[113, 
114] 
Ionizable 
derivates Anionic 
O-carboxymethyl-O-
ethyl- βCD 
Sulfobutylether-βCD 
Soluble at pH>4. [20] 
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Table 2. Some of the currently commercialized pharmaceutical products containing 
cyclodextrins. 
Cyclodextrin Drug Commercial 
Name 
Country 
α-cyclodextrin Alprostadil Caverject Dual Europe 
OP-1206 Opalmon Japan 
PGE1 Prostavastin Japan, Europe 
β-cyclodextrin Benexate HCl Lonmiel, Ulgut Japan 
Cephalosporin Meiact Japan 
Cetirizine Cetrizin Europe 
Chlordiazepoxide Transillium Argentina 
Dexamethasone Glymesason Japan 
Nicotine Nicorette, 
Nicogum 
Europe 
Omeprazol Omebeta Europe 
Piroxicam Brexin Europe 
Tiaprofenic acid Surgamyl Europe 
Methylated-β-cyclodextrin Chloramphenicol Clorocil Europe 
Estradiol Aerodiol Europe 
2-Hydroxypropyl-β-
cyclodextrin 
Cisapride Propulsid Europe 
Hydrocortisone Dexocort Europe 
Indomethacin Indocid Europe 
Itraconazole Sporanox Europe, USA 
Mitomycin Mitozytrex Europe, USA 
2-Hydroxypropyl-γ-
cyclodextrin 
Diclofenac sodium Voltaren Europe 
Tc-99m Teoboroxime CardioTec USA 
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Table 3. Some properties of the most used amphiphilic cyclodextrins. 
Type Characteristics Ref. 
Non-ionic 
amphiphilic 
cyclodextrins 
Lollipop 
cyclodextrins 
Obtained by the grafting of one aliphatic chain 
to 6-amino--cyclodextrin. [115] 
Cup-and-ball 
cyclodextrins 
Synthesized by the introduction of a 
voluminous group, linked to the end of the 
aliphatic chain 
[116] 
Medusa-like 
cyclodextrins 
Obtained by grafting aliphatic chains (length 
C10-C16) to all the primary hydroxyls of the 
CD molecule 
[117, 
118] 
Skirt-shaped 
cyclodextrins 
They consist of ,  and -cyclodextrins per-
modified with aliphatic esters (C2 to C14) on 
the secondary face. 
[119-
121] 
Bouquet-
shaped 
cyclodextrins 
Obtained from the grafting of 14 
polymethylene chains to 3-monomethyl--
cyclodextrin (7 chains on each side of the 
cyclodextrin ring molecule). Per(2,6-di-O-
alkyl)cyclodextrins with alkyl chain propyl, 
pentyl, 3-methylbutyl or dodecyl are also 
bouquet-shaped. 
[122, 
123] 
Cholesteryl 
cyclodextrins 
Cyclodextrin is the hydrophilic head group and 
cholesterol is the hydrophobic part. [124] 
Cationic 
amphiphilic 
cyclodextrins 
[2-amino-O-oligo-(ethyleneoxide)-6-hexylthio]--cyclodextrin has 
an amino group. The oligoethylene glycol group would facilitate 
intracellular drug delivery. 
Other cationic amphiphilic cyclodextrins: polyamino--
cyclodextrins completely substituted by amine groups at the 
position 6 and alkylamino - and -cyclodextrin. 
[65, 
125, 
126] 
Anionic 
amphiphilic 
cyclodextrins 
Acyl-sulfated--cyclodextrins in which the upper rim is 
functionalized with sulfates and the lower with fatty acid esters.  
Fluorine-containing anionic -cyclodextrins functionalized at the 
position 6 by trifluoromethylthio groups.  
Fluorophilic cyclodextrins are obtained combining cyclodextrins 
and a linear perfluorocarbon. 
[127-
130] 
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Figure 1. Diagram representing the mechanism of inhibition of P-glycoprotein by 
cyclodextrins. 
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Figure 2. Representation of the hypothetical mechanism by which the combination 
between cyclodextrins and bioadhesive nanoparticles would promote the oral 
absorption and bioavailability of paclitaxel and other Class IV compounds. 
